• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 24th May 2016

OHE Presentations at HTAi: Tokyo 2016

The 2016 HTAi Annual Meeting was held in Tokyo, Japan, 10-14 May 2016. The focus of the meeting was Informing Health Care Decisions with Values and Evidence. This post contains presentations given by the OHE team. The 2016 HTAi Annual…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The 2016 HTAi Annual Meeting was held in Tokyo, Japan, 10-14 May 2016. The focus of the meeting was Informing Health Care Decisions with Values and Evidence. This post contains presentations given by the OHE team.

The 2016 HTAi Annual Meeting was held in Tokyo, Japan, 10-14 May 2016. The focus of the meeting was Informing Health Care Decisions with Values and Evidence. Several members of the OHE team attended and contributed to the conference. This post contains presentations by the OHE team.

Dimensions of Value, Assessment, and Decision Making by Adrian Towse

In a Breakfast Symposium, Adrian Towse presented on “Dimensions of Value, Assessment, and Decision Making” setting out a framework for (i) Identifying the elements of value (ii) the use of categories or discrete scales to rate / value these elements (iii) how to weight and aggregate these elements to arrive at a “decision on value” and (iv) translation to price and affordability using cost-effectiveness or therapeutic added value approaches.

Dimensions of value, assessment, and decision making from Office of Health Economics

 

How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potential for PBRSAs by Adrian Towse

Adrian Towse presented in a Panel entitled “How can HTA’s in Asia respond to Increased Clinical Uncertainty?” on the  potential for using risk Sharing Agreements, looking at how to implement risk sharing and managed entry agreements, examining case studies and international best practice, identifying barriers and opportunities.

How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potential for PBRSAs from Office of Health Economics

 

Making Value-Based Pricing a Reality – the Case for Multi-Indication Pricing by Adrian Towse

In a lunch time Symposium, Adrian Towse presented on “Making Value-Based Pricing a Reality – the Case for Multi-Indication Pricing”.

Making value-based pricing a reality – the case for multi-indication pricing from Office of Health Economics

 

Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it? by Adrian Towse

In a Panel Session Adrian Towse presented on “Operationalising Value-based Pricing: Do we know what we Value and What we are giving up to get it?” in which he focussed on the evidence in the UK on the opportunity cost of NICE decisions, looking at the Claxton et al. work, the Barnsley et al critique, and work by Karlsberg Schaffer et al. on Wales and on Scotland.

Operationalising Value-based Pricing: Do we know what we value and what we are giving up to get it? from Office of Health Economics

 

Availability, Accessibility and Applicability of Evidence: Transferability – Data Versus Pragmatism by Adrian Towse

In a Panel entitled “Data Versus Pragmatism in the Decision Making Process” Adrian Towse presented on the Transferability of Evidence, highlighting three innovative approaches from OHE authors.

Availability, accessibility and applicability of evidence: Transferability – Data versus pragmatism from Office of Health Economics

 

Options for Formulary Development in Middle-Income Countries by Karla Hernandez-Villafuerte

Options for Formulary Development in Middle-Income Countries by Karla Hernandez-Villafuerte A number of middle-income countries (MICs) are evolving their health systems toward universal health coverage for patient populations. Such countries often have limited drug formularies and some form of essential drugs list. This presentation explores options for bridging the organisation of the health system and its priorities, and provides a framework for developing drug formularies.

OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES from Office of Health Economics

 

Health Economic Evaluation of Bibliometric Trends in Sub-Saharan Africa by Karla Hernandez-Villafuerte 

Collaboration between Sub-Saharan African researchers is important in the generation and transfer of evidence to support the decision making process for health priority setting. This presentation provides an evaluation of collaboration patterns between countries. 

HEALTH ECONOMIC EVALUATION OF BIBLIOMETRIC TRENDS IN SUB-SAHARAN AFRICA from Office of Health Economics
 
Multiple Criteria are already used in HTA by Nancy Devlin

Structured decision making approaches to the inclusion of multiple criteria in HTA by Nancy Devlin Multiple criteria are already used in HTA – so the question isn’t whether to employ multiple criteria, but how this is best done. OHE’s Professor Devlin presented on “structured decision making approaches to the inclusion of multiple criteria in HTA.”

Structured decision making approaches to the inclusion of multiple criteria in HTA from Office of Health Economics
  • EQ-5D and PROMs
  • Presentations

Related News

IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!